Blood Res.  2021 Dec;56(4):209-211. 10.5045/br.2021.2021123.

Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy

• Polprasert C
• Wudhikarn K
• Rojnuckarin P

• KMID: 2524068
• DOI: http://doi.org/10.5045/br.2021.2021123

Figure

• 

  Fig. 1 Immune system and cancer surveillance. In normal situations, CD8+ T-cell recognizes tumor-specific antigens presented by MHC class I and eradicates tumor cells via cytolytic mediators, such as perforin and granzyme (A). Defects of immune surveillance, including dysfunction of PDL1/PDL2 and MHC class I lead to immune escape and cancer progression (B). Abbreviations: GzmB, granzyme B; IFNγ, interferon-gamma; MHC-I, major histocompatibility complex class I; PD-1, programmed death 1; PDL1/PDL2, programmed death-ligand 1/programmed death-ligand 2; PFN, perforin; TCR, T-cell receptor; TNFα, tumor necrosis factor alpha.

Reference

1. Jeong SH. 2020; Extranodal NK/T cell lymphoma. Blood Res. 55:S63–71. DOI: 10.5045/br.2020.S011. PMID: 32719179. PMCID: PMC7386895.

2. Li Z, Xia Y, Feng LN, et al. 2016; Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 17:1240–7. DOI: 10.1016/S1470-2045(16)30148-6. PMID: 31879220.

3. Lin GW, Xu C, Chen K, et al. 2020; Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 21:306–16. DOI: 10.1016/S1470-2045(19)30799-5. PMID: 31879220.

4. Kimura H. 2018; EBV in T-/NK-cell tumorigenesis. Adv Exp Med Biol. 1045:459–75. DOI: 10.1007/978-981-10-7230-7_21. PMID: 29896680.

5. Li Q, Cohen JI. 2019; Epstein-Barr virus and the human leukocyte antigen complex. Curr Clin Microbiol Rep. 6:175–81. DOI: 10.1007/s40588-019-00120-9. PMID: 33094090. PMCID: PMC7577584.

6. Kataoka K, Miyoshi H, Sakata S, et al. 2019; Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 33:1687–99. DOI: 10.1038/s41375-019-0380-5. PMID: 30683910. PMCID: PMC6755969.

7. Muhamad H, Suksawai N, Assanasen T, Polprasert C, Bunworasate U, Wudhikarn K. 2020; Programmed cell death 1 and programmed cell death ligands in extranodal natural killer/T cell lymphoma: expression pattern and potential prognostic relevance. Acta Haematol. 143:78–88. DOI: 10.1159/000500974. PMID: 31330525.

8. Kwong YL, Chan TSY, Tan D, et al. 2017; PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 129:2437–42. DOI: 10.1182/blood-2016-12-756841. PMID: 28188133.

9. Lai J, Xu P, Jiang X, Zhou S, Liu A. 2017; Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer. 17:507. DOI: 10.1186/s12885-017-3501-4. PMID: 28754096. PMCID: PMC5534108.

10. Polprasert C, Takeuchi Y, Makishima H, et al. 2021; Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leuk Lymphoma. 62:95–103. DOI: 10.1080/10428194.2020.1821011. PMID: 32964767.

11. de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB. 2019; Molecular pathogenic pathways in extranodal NK/T cell lymphoma. J Hematol Oncol. 12:33. DOI: 10.1186/s13045-019-0716-7. PMID: 30935402. PMCID: PMC6444858.

12. Jiang L, Gu ZH, Yan ZX, et al. 2015; Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 47:1061–6. DOI: 10.1038/ng.3358. PMID: 26192917.